Mulchandani Ranya, Tiseo Katie, Nandi Arindam, Klein Eili, Gandra Sumanth, Laxminarayan Ramanan, Van Boeckel Thomas
Health Geography and Policy Group, ETH Zurich, Zurich, Switzerland.
Population Council, New York, New York, USA.
BMJ Public Health. 2025 May 27;3(1):e002411. doi: 10.1136/bmjph-2024-002411. eCollection 2025.
Inappropriate antibiotic use is a major driver of antimicrobial resistance. However, the scope of literature and its prevalence across world regions remain largely unknown, as do the most common indicators and study designs used. In this study, we summarised the current literature on inappropriate use of antibiotics by world regions. We also provided the first global estimates of the overall amount of antibiotics that are potentially used inappropriately each year.
We considered both patient and provider-mediated inappropriate antibiotic use. We reviewed 412 studies published between 2000 and 2021 and used beta regression and marginal contrasts to compare prevalence of inappropriate use by study design, indicator, world region, and national income level. Country-level sales of antibiotics from 2022 were combined with inappropriate antibiotic use estimates derived from two study designs (clinical audits and patient interviews) and one indicator (lack of indication) to estimate the amount of antibiotics inappropriately used globally.
Clinical audits (50.1%, 208/412) and 'non-prescription' use (37.1%, 153/412) were the most common study design and indicator, respectively, used to estimate inappropriate antibiotic use. Inappropriate antibiotic use prevalence was 6% higher in low-income and middle-income than in high-income countries. However, this difference disappeared after accounting for a proxy of access to care: physicians per capita. Globally, based on clinical audits, patient interviews and lack of indication, the estimated proportion of inappropriate antibiotic use was 29.5%, 36.5% and 30.8%, respectively, with an average of ~30% (13 000 000 kg) the equivalent of the annual antibiotic consumption in China.
Inappropriate antibiotic use is highly prevalent across all countries regardless of national income level, with a third of global antibiotic consumption potentially due to unnecessary prescription ('lack of indication'). Antibiotic stewardship efforts and defining internationally standardised indicators are needed to track progress in reducing the occurrence of inappropriate antibiotic use where necessary, as well as identifying gaps in access to care.
抗生素使用不当是抗菌素耐药性的主要驱动因素。然而,相关文献的范围及其在世界各地区的流行情况在很大程度上仍然未知,所使用的最常见指标和研究设计也是如此。在本研究中,我们总结了世界各地区目前关于抗生素使用不当的文献。我们还首次对每年可能存在使用不当情况的抗生素总量进行了全球估算。
我们考虑了患者和医疗服务提供者介导的抗生素使用不当情况。我们回顾了2000年至2021年间发表的412项研究,并使用贝塔回归和边际对比来比较不同研究设计、指标、世界地区和国民收入水平下使用不当情况的流行率。将2022年各国的抗生素销售量与从两种研究设计(临床审计和患者访谈)和一个指标(缺乏用药指征)得出的抗生素使用不当估计值相结合,以估算全球抗生素使用不当的量。
临床审计(50.1%,208/412)和“非处方”使用(37.1%,153/412)分别是用于估计抗生素使用不当的最常见研究设计和指标。低收入和中等收入国家抗生素使用不当的流行率比高收入国家高约6%。然而,在考虑了医疗服务可及性的一个替代指标(人均医生数量)后,这种差异消失了。在全球范围内,基于临床审计、患者访谈和缺乏用药指征,估计的抗生素使用不当比例分别为29.5%、36.5%和30.8%,平均约为30%(约13000000千克),相当于中国的年抗生素消费量。
无论国民收入水平如何,抗生素使用不当在所有国家都非常普遍,全球三分之一的抗生素消费可能是由于不必要的处方(“缺乏用药指征”)。需要开展抗生素管理工作并定义国际标准化指标,以跟踪在减少抗生素使用不当发生方面的进展,并确定医疗服务可及性方面的差距。